Mastocytosis

Chemical Immunology and Allergy

Volumn 95, Issue , 2010, Pages 110-124

  Brockow, Knut ^a   Metcalfe, Dean D ^b  

^a TECHNICAL UNIVERSITY OF MUNICH   (Germany)

^b NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CD2 ANTIGEN; CLADRIBINE; INTERLEUKIN 2 RECEPTOR ALPHA; OMALIZUMAB; TRYPTASE;

ANAPHYLAXIS; CELL STRUCTURE; CLINICAL FEATURE; HUMAN; IMMUNOHISTOCHEMISTRY; MAST CELL; MASTOCYTOSIS; PHENOTYPE; PRIORITY JOURNAL; REVIEW; SKIN DEFECT;

ANAPHYLAXIS; ANTIGENS, CD; BIOLOGICAL MARKERS; CELL DEGRANULATION; CELL MOVEMENT; CELL PROLIFERATION; CLONE CELLS; HUMANS; MAST CELLS; MASTOCYTOSIS; MUTATION; PROTO-ONCOGENE PROTEINS C-KIT; SKIN DISEASES; TRYPTASES;

EID: 77954837863     PISSN: 16602242     EISSN: None     Source Type: Book Series    
DOI: 10.1159/000315946     Document Type: Review

References (46)

1. Metz M, Brockow K, Metcalfe DD, Galli SJ: Mast cells, basophils and mastocytosis; in Rich, Fleisher, Shearer, et al (eds): Clinical Immunology -Principles and Practice. New York, Mosby, 2008, pp 22.21-22.16.
2. Metcalfe DD: Mast cells and mastocytosis. Blood 2008;112:946-956.
3. Tkaczyk C, Horejsi V, Iwaki S, et al: NTAL phosphorylation is a pivotal link between the signaling cascades leading to human mast cell degranulation following Kit activation and Fc epsilon RI aggregation. Blood 2004;104:207-214.
4. Brockow K, Jofer C, Behrendt H, Ring J: Anaphylaxis in patients with mastocytosis: a study on history, clinical features and risk factors in 120 patients. Allergy 2008;63:226-232.
5. Gonzalez de Olano D, de la Hoz Caballer B, Nunez Lopez R, et al: Prevalence of allergy and anaphylactic symptoms in 210 adult and pediatric patients with mastocytosis in Spain: a study of the Spanish Network on Mastocytosis (REMA). Clin Exp Allergy 2007;37:1547-1555.
6. Akin C, Scott LM, Kocabas CN, et al: Demonstration of an aberrant mast-cell population with clonal markers in a subset of patients with 'idiopathic' anaphylaxis. Blood 2007;110:2331-2333.
7. Bonadonna P, Perbellini O, Passalacqua G, et al: Clonal mast cell disorders in patients with systemic reactions to Hymenoptera stings and increased serum tryptase levels. J Allergy Clin Immunol 2009;123:680-686.
8. Sonneck K, Florian S, Mullauer L, et al: Diagnostic and subdiagnostic accumulation of mast cells in the bone marrow of patients with anaphylaxis: monoclonal mast cell activation syndrome. Int Arch Allergy Immunol 2007;142:158-164.
9. Brockow K: Urticaria pigmentosa. Immunol Allergy Clin North Am 2004;24:287-316.
10. Valent P, Akin C, Escribano L, et al: Standards and standardization in mastocytosis: consensus statements on diagnostics, treatment recommendations and response criteria. Eur J Clin Invest 2007;37:435-453.
11. Brockow K, Metcalfe DD: Mastocytosis. Curr Opin Allergy Clin Immunol 2001;1:449-454.
12. Akin C, Metcalfe DD: The biology of Kit in disease and the application of pharmacogenetics. J Allergy Clin Immunol 2004;114:13-19.
13. Longley BJ Jr, Morganroth GS, Tyrrell L, et al: Altered metabolism of mast-cell growth factor (c-kit ligand) in cutaneous mastocytosis. N Engl J Med 1993;328:1302-1307.
14. Brockow K, Akin C, Huber M, et al: Levels of mastcell growth factors in plasma and in suction skin blister fluid in adults with mastocytosis: correlation with dermal mast-cell numbers and mast-cell tryptase. J Allergy Clin Immunol 2002;109:82-88.
15. Orfao A, Garcia-Montero AC, Sanchez L, Escribano L: Recent advances in the understanding of mastocytosis: the role of KIT mutations. Br J Haematol 2007;138:12-30.
16. Nagata H, Worobec AS, Oh CK, et al: Identification of a point mutation in the catalytic domain of the protooncogene c-kit in peripheral blood mononuclear cells of patients who have mastocytosis with an associated hematologic disorder. Proc Natl Acad Sci USA 1995;92:10560-10564.
17. Garcia-Montero AC, Jara-Acevedo M, Teodosio C, et al: KIT mutation in mast cells and other bone marrow hematopoietic cell lineages in systemic mast cell disorders: a prospective study of the Spanish Network on Mastocytosis (REMA) in a series of 113 patients. Blood 2006;108:2366-2372.
18. Daley T, Metcalfe DD, Akin C: Association of the Q576R polymorphism in the interleukin-4 receptor α chain with indolent mastocytosis limited to the skin. Blood 2001;98:880-882.
19. Gilfillan AM, Peavy RD, Metcalfe DD: Amplification mechanisms for the enhancement of antigen-mediated mast cell activation. Immunol Res 2009;43:15-24.
20. Brockow K, Akin C, Huber M, Metcalfe D: Assessment of the extent of cutaneous involvement in children and adults with mastocytosis: relationship to symptomatology, tryptase levels, and bone marrow pathology. J Am Acad Dermatol 2003;48:508-516.
21. Valent P, Horny H, Li C, et al: Mastocytosis; in Jaffe E, Harris N, Stein H, Vardiman J (eds): World Health Organization Classification of Tumors. Pathology and Genetics of Tumors of Hematopoietic and Lymphoid Tissue. Lyon, IARC Press, 2001, pp 293-302.
22. Simpson JK, Brockow K, Turner ML, et al: Generalized erythematous macules and plaques associated with flushing, repeated syncope, and refractory anemia. J Am Acad Dermatol 2002;46:588-590.
23. Caplan RM: The natural course of urticaria pigmentosa. Arch Dermatol 1963;87:146-157.
24. Horan RF, Austen KF: Systemic mastocytosis: retrospective review of a decade's clinical experience at the Brigham and Women's Hospital. J Invest Dermatol 1991;96:5S-13S.
25. Travis WD, Li CY, Bergstralh EJ, et al: Systemic mast cell disease. Analysis of 58 cases and literature review Medicine (Baltimore) 1988;67:345-368 Published erratum appears in Medicine (Baltimore) 1990;69:34.
26. Brockow K, Ring J, Przybilla B, Ruëff F: Klinik und Therapie der Anaphylaxie bei Mastozytose. Allergo J 2008;17:556-562.
27. Johansson SG, Bieber T, Dahl R, et al: Revised nomenclature for allergy for global use: report of the Nomenclature Review Committee of the World Allergy Organization, October 2003. J Allergy Clin Immunol 2004;113:832-836. (Pubitemid 38608590)
28. Sampson HA, Munoz-Furlong A, Campbell RL, et al: Second symposium on the definition and management of anaphylaxis: summary report-Second National Institute of Allergy and Infectious Disease/ Food Allergy and Anaphylaxis Network symposium. J Allergy Clin Immunol 2006;117:391-397.
29. Ludolph-Hauser D, Rueff F, Fries C, et al: Constitutively raised serum concentrations of mast-cell tryptase and severe anaphylactic reactions to Hymenoptera stings. Lancet 2001;357:361-362.
30. Oude Elberink JN, de Monchy JG, Kors JW, et al: Fatal anaphylaxis after a yellow jacket sting, despite venom immunotherapy, in two patients with mastocytosis. J Allergy Clin Immunol 1997;99:153-154.
31. Rueff F, Placzek M, Przybilla B: Mastocytosis and Hymenoptera venom allergy. Curr Opin Allergy Clin Immunol 2006;6:284-288.
32. Florian S, Krauth MT, Simonitsch-Klupp I, et al: Indolent systemic mastocytosis with elevated serum tryptase, absence of skin lesions, and recurrent severe anaphylactoid episodes. Int Arch Allergy Immunol 2005;136:273-280.
33. Gonzalez de Olano D, Alvarez-Twose I, Esteban-Lopez MI, et al: Safety and effectiveness of immunotherapy in patients with indolent systemic mastocytosis presenting with Hymenoptera venom anaphylaxis. J Allergy Clin Immunol 2008;121:519-526.
34. Schwartz LB: Diagnostic value of tryptase in anaphylaxis and mastocytosis. Immunol Allergy Clin N Am 2006;451-463.
35. Escribano L, Orfao A, Diaz-Agustin B, et al: Indolent systemic mast cell disease in adults: immunophenotypic characterization of bone marrow mast cells and its diagnostic implications. Blood 1998;91:2731-2736. (Pubitemid 28227522)
36. Horny HP, Valent P: Histopathological and immunohistochemical aspects of mastocytosis. Int Arch Allergy Immunol 2002;127:115-117.
37. Sotlar K, Escribano L, Landt O, et al: One-step detection of c-kit point mutations using peptide nucleic acid-mediated polymerase chain reaction clamping and hybridization probes. Am J Pathol 2003;162:737-746.
38. Ring J, Brockow K, Duda D, et al: Akuttherapie anaphylaktischer Reaktionen. Allergo J 2007;16:420-434.
39. Carter MC, Uzzaman A, Scott LM, et al: Pediatric mastocytosis: routine anesthetic management for a complex disease. Anesth Analg 2008;107:422-427.
40. Bonadonna P, Zanotti R, Caruso B, et al: Allergenspecific immunotherapy is safe and effective in patients with systemic mastocytosis and Hymenoptera allergy. J Allergy Clin Immunol 2008;121: 256-257.
41. Rueff F, Wenderoth A, Przybilla B: Patients still reacting to a sting challenge while receiving conventional Hymenoptera venom immunotherapy are protected by increased venom doses. J Allergy Clin Immunol 2001;108:1027-1032.
42. Kontou-Fili K: High omalizumab dose controls recurrent reactions to venom immunotherapy in indolent systemic mastocytosis. Allergy 2008;63: 376-378.
43. Carter MC, Robyn JA, Bressler PB, et al: Omalizumab for the treatment of unprovoked anaphylaxis in patients with systemic mastocytosis. J Allergy Clin Immunol 2007;119:1550-1551.
44. Hartmann K, Siebenhaar F, Belloni B, et al: Topical treatment with the raft modulator miltefosine -a novel therapeutic option for mastocytosis? Br J Dermatol, in press.
45. Akin C, Brockow K, D'Ambrosio C, et al: Effects of tyrosine kinase inhibitor STI571 on human mast cells bearing wild-type or mutated c-kit. Exp Hematol 2003;31:686-692.
46. Akin C, Fumo G, Yavuz AS, et al: A novel form of mastocytosis associated with a transmembrane c-kit mutation and response to imatinib. Blood 2004;103: 3222-3225.